Trial Profile

A phase II clinical study of RT-102

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 18 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RT-102 (Primary)
Indications Osteoporosis
Focus Therapeutic Use
Sponsors Rani Therapeutics

Most Recent Events

14 Dec 2023 According to a Rani Therapeutics media release, the trial is expected to start in 2024
11 Aug 2023 According to a Rani Therapeutics media release, Initiation of Phase 2 study of RT-102 for osteoporosis expected in the second half of 2023.
22 Mar 2023 According to a Rani Therapeutics media release, following feedback from a pre-IND meeting with FDA, the company believes that a 505(b)(2) pathway is suitable for the development of RT-102 in the U.S.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com